The Radcliffe Department of Medicine (RDM) is a Department within the Medical Sciences Division. The Department was created in 2012 to bring together a number of clinical academic units into a coherent grouping in order to add value to one another and to enhance further the interfaces between basic science programmes, including those in the Weatherall Institute of Molecular Medicine, and the Oxford University Hospitals Trust. RDM provides a focus around cardiovascular medicine, acute stroke, diabetes, endocrinology & metabolism, haematology, immunology and experimental therapeutics and is underpinned by excellence in molecular medicine and clinical laboratory science.
With broad research interests and strengths in translating molecular and cellular science across multiple disease areas its remit spans basic research through to clinical application.
RDM is one of the largest Departments in the University, with over 500 staff and an annual turnover of approximately £50m. It has a strong clinical presence on both the John Radcliffe and Churchill Hospital sites in Oxford. It teaches a significant part of the clinical student curriculum and has approximately 100 postgraduate research students.
The Department is led by Professor Hugh Watkins supported by a Management Committee which provides strategic oversight and assists with major operational decisions.
The RDM includes:
The Department operates as a devolved structure, with the above 5 units having their own visible identity, leadership and strategy. They are supported by a small central administrative team which is led by Lynn Clee, Head of Administration and Finance for RDM.